Welcome to the

Vascular Immunobiology Lab

Principal investigator: Dr. Oliveira

Our Research

Pathogen-associated Inflammatory Cardiovascular & Pulmonary Diseases

S. mansoni egg (green) interaction with pulmonary endothelial cells. White: Cav-1; Red: VE-cad; Blue: nuclei. Note a Cav-1+EV at the bottom.

Murine plasma extracellular vesicles were isolated and loaded into a Nanoparticle Analyzer (Nanosight) to quantify particle concentration and size.

Pulmonary Vascular Diseases, especially Pulmonary Arterial Hypertension (PAH), have been the focus of our research effort. PAH is a life-threatening disease with no cure, characterized by hyperproliferation of vascular cells, including endothelial cells. The hyperproliferation of vascular cells eventually obstructs the lung vasculature leading to irreversible lesions that collectively drive up the pulmonary pressure to life-threatening levels. Although the primary cause of non-infectious PAH is not fully understood, several studies indicate it results from chronic pulmonary inflammation. Curiously, infection by the parasite Schistosoma mansoni recapitulates aspects of widespread pulmonary inflammation that lead to PAH, providing a unique model where molecular alterations leading to vascular cell hyperproliferation can be unraveled and hopefully leveraged for the development of clinical solutions for PAH.

Additional Research Interests

The Gut-Mesentery-Lung Axis

Anesthesia & Vascular Diseases

Schistosomiasis-associated PAH evolves in response to S. mansoni egg-associated obliteration and remodeling of the lung vasculature, which can lead to heart failure and death. Primarily, the parasites lay their eggs into the mesenteric circulation, either crossing the intestinal wall to achieve the gut’s lumen or allocating into other organs, such as the lungs and liver, increasing its pressure. Liver bypass via collateral circulation can alleviate the parasite-induced pressure in the portal system, but it also allows translocation of eggs, toxins, and antigens into the lungs, ultimately causing PAH. Understanding how these systems communicate is essential to uncover the onset and prevent the progression of chronic diseases (OLIVEIRA, 2022 – ATVB). 

In collaboration with our peers, we observed that sevoflurane, a volatile anesthetic, is a protective agent during sepsis-induced inflammation and vascular injury. More specifically, we helped to identify that sevo exposure leads to inducible nitric oxide synthase (iNOS) expression in macrophages, contributing to killing bacteria in the peritoneum and helping to improve survival during sepsis-induced inflammation. Sepsis affects millions of patients worldwide, causing hundreds of thousands of deaths. Thus, it is important to determine the molecular mechanisms of this clinical condition to develop potential novel therapeutic approaches to reduce sepsis-associated mortality (GERBER, FEHR, OLIVEIRA, et al. 2019 – Anesthesiology).

Latest News

New Publication

ATVB 2022

Dr. Oliveira discusses aspects of the gut-mesentery-lung axis in the development of PAH.

Student’s Scholarship

Lizzy Villarreal

Lizzy got a scholarship!

Funding Award


We have been awarded a K01 from the National Institutes of Health (NIH)!

Upcoming Events

American Thoracic Society 2022

AHA Vascular Discovery 2022

15th Annual World Congress on PVD

Website Design by

Pedro Casanova / Graphic Designer